Search results
CHMP opinion. European Commission decision. Overview. Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
EMA by emailing p-pv-emerging-safety-issue@ema.europa.eu; the relevant competent authority or authorities in the Member State(s) concerned. To support reporting to Member States, EMA has published a list of national contact points: Emerging safety issues (ESI) contact points at the national competent authority (NCA) level
• EMA by emailing p-pv-emerging-safety-issue@ema.europa.eu; • the relevant competent authority or authorities in the Member State(s) concerned. To support reporting to Member States, EMA has published a list of national contact points:
A few incidents of fraud and phishing attempts using hoax messages, letters and scam phone calls purporting to be from OLAF, the European Anti-Fraud Office have been detected.
Do głównych zadań Europejskiej Agencji Leków należy dopuszczanie do obrotu produktów leczniczych w UE i ich kontrolowanie. Przedsiębiorstwa farmaceutyczne składają do EMA wniosek o pozwolenie na dopuszczenie do obrotu danego produktu leczniczego. Pozwolenia wydaje Komisja Europejska.
Co zawiera i jak działa Emend - kapsułki twarde? Zapobieganie nudnościom i wymiotom związanym z chemioterapią przeciwnowotworową o dużym i umiarkowanym ryzyku wymiotów u dorosłych i młodzieży w wieku od 12 lat. Preparat stosuje się w leczeniu skojarzonym.
If you would like to make a complaint about any aspect of the Agency's work, please write to: Executive Director. European Medicines Agency. PO Box 71010. 1008 BA Amsterdam. The Netherlands. To make a complaint by email, use our online form to Send a question to the EMA.
